Helicobacter pylori-associated antibodies in patients with duodenal ulcer,gastric and oesophageal adenocarcinoma

Objective To associate Helicobacter pylori-associated antibodies with clini cal disease in groups of patients with duodenal ulcer, gastric adenocarcino ma, oesophageal adenocarcinoma and normal mucosa. Design Prospective observational sero-epidemiology study. Identification of consecutive in-patients with duodenal ulcer, gastric adenocarcinoma, oesop hageal adenocarcinoma and normal mucosa. Analyses of sera for antibodies to whole H. pylori, Cag A and Vac A antigens using ELISA and Western blot. St atistical analyses. Setting Walsgrave Hospital, Coventry, a district general hospital that serv es a population of 350 000, Participants Consecutive in-patients with an endoscopic diagnosis of duoden al ulcer (n = 31), gastric adenocarcinoma (n = 31), oesophageal adenocarcin oma (n = 40) and normal mucosa (n = 46). Main outcome measures A profile of antibodies was constructed for each pati ent group and between-group comparisons were made, A logistic regression mo del determined the H. pylori-associated antibody that could best predict a patient's diagnosis, A discriminatory power for each antibody was calculate d. Results Whole H. pylori, Cag A and Vac A antibodies are found more commonly in duodenal ulcer patients when compared to oesophageal adenocarcinoma (P< 0.003) and normal mucosa patients (P< 0.015), Similarly, gastric adenocarc inoma patients have antibodies to whole ii. pylori, Cag A and Vac A more fr equently than oesophageal adenocarcinoma (P< 0.002) and normal mucosa patie nts (P< 0.006). Vac A antibodies discriminate between duodenal ulcer/gastri c adenocarcinoma and oesophageal adenocarcinoma/normal mucosa patients (odd s ratio 5.56, log likelihood -90.06, P< 0.001) more effectively than Cag A antibodies (odds ratio 4.17, log likelihood -91.88, P< 0.001). Conclusions Similar profiles of H. pylori-associated antibodies are seen in patients with duodenal ulcer and gastric adenocarcinoma, confirming that v irulent H. pylori are involved in the pathogenesis of both diseases. Antibo dies to Vac A could be used to identify patients at increased risk of devel oping H. pylori-associated disease. fur J Gastroenterol Hepatol 11:503-509 (C) 1999 Lippincott Williams & Wilkins.